Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PM8002 (Pumitamig) Monotherapy in Advanced Solid Tumors
NCT05918445Phase 2Recruiting
- Sponsor
- Biotheus
- Start
- Mar 2021
- Primary completion
- Nov 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of pumitamig in solid tumor, sponsored by Biotheus. Started Mar 2021; status: recruiting.
02
Drugs
pumitamig
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05918445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05918445.